GLP-1 employer benefits cost

GLP-1s in Employee Health Plans: Cost Forecasts & Mitigation Tactics

November 25, 2025

Key Takeaways

GLP-1s drive unprecedented cost increases: These medications caused drug spending growth to surge from 2.1% to 12.8%, with total GLP-1 spending increasing over 500% between 2018-2023.
Premium hikes are substantial and unavoidable: Simulation models predict health insurance premium increases of 5.3% to 13.8% for employers covering GLP-1s, even with cost-sharing strategies.
Strategic cost management requires multi-layered approaches: Employers are implementing stricter prior authorization, BMI thresholds, lifestyle program requirements, and specialized HRAs to control expenses.
Long-term usage creates ongoing financial commitment: GLP-1s require lifelong therapy for effectiveness, with patients regaining weight when treatment stops, making budget planning critical.
Alternative solutions can bridge cost gaps: Programs like Inside Rx can help employees save up to 80% on prescription medications, including GLP-1 medications, allowing employers to maintain benefits while controlling direct costs.

A clear bottle labeled GLP1, represents medications associated with GLP1 therapy

The Inside Rx Blog

Get the Inside Scoop on tips & tricks that may help your family save on prescriptions!

Subscribe to stay up to date with the latest news and tips

GLP-1 medications have created unprecedented financial strain on employer health plans. These drugs shifted from position 32 to the top pharmacy expense category for numerous organizations. Annual costs for GLP-1 drugs (glucagon-like peptide 1 receptor agonists) range from $8,000 to $10,000 per user, placing substantial pressure on plan budgets.

The medications demonstrate clinical efficacy for Type 2 diabetes treatment and weight management, yet their expense creates operational challenges for benefits administrators. Data shows 91% of large employers express concern about long-term financial implications of GLP-1 weight management coverage. More than 57 million privately insured adults, representing over 40% of this population, meet clinical criteria for GLP-1 therapy. This eligibility scope amplifies the potential cost burden significantly.

Employers now evaluate whether sustained GLP-1 coverage remains financially viable within existing plan structures. Key considerations include determining appropriate coverage parameters, establishing sustainable cost management protocols, and maintaining plan accessibility for clinically appropriate candidates.

This analysis examines GLP-1 medication impacts on employer healthcare expenses and outlines specific cost management strategies that maintain employee health support while addressing budget constraints.

Why GLP-1s Are Driving Up Employer Healthcare Costs

GLP-1 medication expenses now represent a critical cost driver within corporate health plan structures. Organizations nationwide report difficulty balancing escalating pharmaceutical expenses against employee healthcare requirements.

GLP-1s as a top driver of pharmacy spend

Traditional drug spending growth rates accelerated from 2.1% in 2021 to 12.8% in 2024, with GLP-1s functioning as the primary accelerant. These medications advanced from position #32 to become the leading pharmacy expense category for numerous companies. Total GLP-1 drug expenditures increased more than 500% between 2018 and 2023, escalating from $13.7 billion to $71.7 billion.

Weight management medications now represent 46.8% of all drug spending increases. Ozempic expenditures expanded from $410 million in 2018 to $26.42 billion by 2023. Multiple employers document GLP-1 cost increases of 30-50% annually.

Cost comparison: GLP-1 users vs non-users

Healthcare expense differentials between GLP-1 users and non-users demonstrate significant variance. Two-year research data indicates GLP-1 users experienced total healthcare costs rising from $12,695 pre-treatment to $20,165 in year one and $18,507 in year two. Non-users maintained lower expense levels at $11,406, $11,882, and $13,012 across identical timeframes.

GLP-1 therapy generated additional annual healthcare costs of approximately $7,000 in the first year and $4,200 in the second year versus control groups. These figures correspond with established data showing diabetic patients incur medical expenditures 2.6 times higher than non-diabetic individuals.

The challenge of off-label and long-term use

GLP-1 medications require continuous administration for sustained clinical benefit. Medical research indicates "All the evidence right now suggests that these therapies are therapies for life”. Treatment discontinuation frequently results in weight regain, establishing ongoing therapeutic requirements.

Patient adherence rates present additional complications. Only 32% of GLP-1 users continued therapy beyond one year, with rates declining to 15% by year two. Approximately one-third of patients discontinue treatment within four weeks, prior to achieving therapeutic dosing levels.

Programs such as Inside Rx offer potential cost mitigation opportunities for employers. These discount programs can reduce employee prescription expenses by up to 80% for GLP-1 medications, maintaining treatment accessibility while addressing plan cost pressures.

Forecasting the Financial Impact of GLP-1 Coverage

Cost projection analysis for GLP-1 medications requires evaluation of multiple variables affecting employer healthcare budgets.

Simulation models: cost scenarios and premium hikes

Financial modeling demonstrates substantial premium impacts for organizations covering these medications. Current drug pricing scenarios yield premium increases ranging from 5.3% to 13.8%, with variations based on implementation parameters. Reduced-price scenarios at $200 monthly still produce increases of 1% to 3.9%. Medicare projections estimate $66 billion in costs over one decade, with approximately $18 billion offset through reduced hospitalization expenses.

How adherence and eligibility affect total spend

Medication adherence patterns directly influence cost projections. Perfect adherence scenarios generate premium increases several percentage points above models using realistic adherence assumptions. Eligibility expansion creates multiplicative cost effects—coverage extension to overweight populations beyond those with obesity or diabetes substantially increases premium burden through enlarged eligible populations.

The role of cost-sharing and copays

Cost-sharing mechanisms provide partial financial mitigation. A $90 copay structure reduces premium increases by 1-2 percentage points across modeling scenarios. Higher out-of-pocket expenses correlate with reduced adherence patterns; patients in the highest cost quartile ($80-$3,375 for 30-day supply) demonstrate significantly elevated nonadherence rates. This creates tension between employer cost control objectives and therapeutic effectiveness requirements.

Future price trends and biosimilar potential

Biosimilar medications represent potential cost reduction opportunities. No GLP-1 biosimilars currently exist, though comparable drug categories show significant savings potential. Biosimilars have generated approximately $445 billion in healthcare system savings. These alternatives could serve as cost deflation mechanisms for specialty medication categories. Current market conditions may benefit from discount programs such as Inside Rx, which provides up to 80% savings on GLP-1 medications for eligible employees.

Tactics Employers Are Using to Manage GLP-1 Costs

Organizations implement targeted strategies to control GLP-1 expenses while preserving necessary medication access for employees.

Stricter prior authorization and diagnosis verification

Organizations have enhanced prior authorization protocols to ensure appropriate medication utilization. Care teams document medical necessity through detailed chart records that include weight progression data, previous lifestyle intervention attempts, and obesity-related comorbidity assessments. Healthcare providers must satisfy complex documentation requirements. Electronic prior authorization systems provide immediate access to insurance-specific approval criteria.

BMI thresholds and time-limited coverage

Employers modified Body Mass Index eligibility requirements to control costs. Standard BMI requirements increased from 30 to 32 or 35 for many plans. A BMI threshold of 35 maintains eligibility for 13% of adults (14.6 million individuals) covered under employer plans. The University of Michigan established two-year coverage limits for weight loss applications.

Incentivizing lifestyle programs and coaching

Organizations now mandate behavioral support programs alongside medication therapy. Currently, 34% of companies require dietitian consultations, case management, or structured lifestyle programs for GLP-1 coverage eligibility, a significant increase from 10% in the previous year. Cigna Healthcare developed programs requiring lifestyle management participation with scheduled check-ins and digital progress monitoring.

Excluding GLP-1s for weight loss from plans

Some employers eliminated weight management GLP-1 coverage entirely. Allina Health terminated coverage for Saxenda, Wegovy, and Zepbound effective January 2025 to preserve premium affordability. Colorado's state plan removed GLP-1 obesity coverage while maintaining existing user access through increased copayments from $30 to $120.

Using Inside Rx and pharmacy discount programs

Discount programs supplement traditional cost-control measures. Inside Rx integration as an employee benefit enables workers to save up to 80% on GLP-1 medications across 60,000 participating pharmacies. This discount program functions independently from insurance coverage and requires no registration processes.

Alternative Coverage Models and Long-Term Planning

Employers evaluate structural modifications to address sustained GLP-1 cost pressures while preserving essential health benefits.

Health Reimbursement Arrangements (HRAs)

HRAs designed for GLP-1 medications offer employers defined budget control mechanisms. These employer-funded accounts provide tax benefits while establishing fixed annual reimbursement parameters. HRA structures accommodate integration with current health plans or function as excepted benefit HRAs, enabling organizations to reimburse GLP-1 expenses separately from primary plan benefits. Sentinel Group developed a specialized HRA targeting GLP-1 medications, featuring streamlined claims processing and customizable eligibility requirements.

Vendor partnerships for wraparound support

Specialized vendor partnerships demonstrate improved clinical outcomes and cost management. Clinical data indicates medication combined with behavioral programs produces 54% more effective for weight loss results compared to medication-only approaches. Personify Health operates GLP-1 support services through its Transform Weight Management program. The program deploys GLP-1-trained coaches and creates individualized care protocols to optimize medication effectiveness and support sustained health outcomes.

Balancing employee demand with sustainability

Market projections indicate the GLP-1 sector will exceed $100 billion by 2030. Employers balance workforce health requirements against fiscal constraints. Inside Rx integration as an employee benefit enables workers to achieve up to 80% savings on prescription medications, including GLP-1 medications, while maintaining employer budget predictability.

The Inside Rx prescription discount card works like a coupon to save on the cost of prescription medication at your local pharmacy.

Ozempic

^$ 1,101.99

Pen Injector, 1/0.75(3) (Package Of 3.0 Ml)

1 Package

Zepbound

^$ 391.24

Vial, 2.5 Mg/0.5

1 Package

Conclusion

GLP-1 medications represent a substantial cost management challenge for employer health plans. These medications now constitute the primary pharmacy expense for multiple organizations, with annual user costs between $8,000-$10,000, creating measurable budget impacts. Premium increase projections of 5.3% to 13.8% for coverage providers require immediate strategic attention.

Effective cost management demands multi-faceted approaches that preserve clinical access while controlling expenditures. Prior authorization protocols, BMI eligibility parameters, and lifestyle program integration demonstrate measurable cost reduction potential without eliminating coverage entirely. Structural alternatives including specialized HRAs and vendor partnerships provide sustained budget management frameworks.

GLP-1 therapy requires continuous administration for clinical effectiveness, yet the medications provide documented benefits for diabetes management and weight reduction. Coverage decisions must account for the substantial eligible population, over 57 million privately insured adults, while maintaining financial sustainability.

Multiple cost management options allow organizations to balance employee health support with budgetary constraints. Programs such as Inside Rx provide employees with potential savings up to 80% on prescription medications, including GLP-1 medications, across extensive pharmacy networks. Optimal strategies integrate direct cost controls with accessibility programs for clinically appropriate candidates.

The GLP-1 market expansion continues, requiring ongoing adaptation of coverage strategies. Organizations implementing the outlined cost management approaches can establish sustainable frameworks for this expanding therapeutic category while maintaining essential employee health benefits.

References

Topics:

Prescription Savings Living with Diabetes Health Tips for Women Health Tips for Men